Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 9/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 9/20 | 0.34 |
| ▸ | RELA | Q04206 | 9/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15827402 | 0.75 | KDM4E (0.58) | CYP1A2KDM4EMAPTHSD17B10 | |
| SCHEMBL12913705 | 0.73 | VDR (0.45) | CYP1A2KDM4EMAPTNFKB1NFKB2 | |
| SCHEMBL21160631 | 0.72 | HTR1A (0.41) | CYP1A2KDM4EMAPTNFKB1NFKB2 | |
| SCHEMBL21160632 | 0.72 | CYP1A2 (0.52) | CYP1A2KDM4EMAPT | |
| SCHEMBL21160841 | 0.71 | CYP1A2 (0.71) | CYP1A2KDM4EMAPTNFKB1NFKB2 | |
| SCHEMBL20530689 | 0.69 | MEN1 (0.41) | KDM4EMAPTNFKB1HSD17B10 | |
| SCHEMBL20530696 | 0.69 | MEN1 (0.41) | KDM4EMAPTNFKB1HSD17B10 | |
| SCHEMBL21160630 | 0.69 | CYP1A2 (0.49) | CYP1A2KDM4EMAPTHSD17B10 | |
| SCHEMBL12913695 | 0.69 | GAA (0.49) | CYP1A2KDM4EMAPTNFKB1NFKB2 | |
| SCHEMBL21160440 | 0.68 | VDR (0.38) | CYP1A2KDM4EMAPTCYP1B1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11215928-B2 | Composition for resist underlayer film formation, resist underlayer film and method for forming the same, and production method of a patterned substrate | JSR CORPORATION (JP) | 2022-01-04 | — | — | US | disclosed |
| US-20190212650-A1 | COMPOSITION FOR RESIST UNDERLAYER FILM FORMATION, RESIST UNDERLAYER FILM AND METHOD FOR FORMING THE SAME, AND PRODUCTION METHOD OF A PATTERNED SUBSTRATE | JSR CORPORATION (JP) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11215928-B2 | Composition for resist underlayer film formation, resist underlayer film and method for forming the same, and production method of a patterned substrate | TOP1, OXA1L, RER1 | CYP1A2 273/4885KDM4E 1890/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.